Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 26 Sep 24 424B3 Prospectus supplement
- 10 Sep 24 424B3 Prospectus supplement
- 24 Jul 24 424B3 Prospectus supplement
- 14 Jun 24 424B3 Prospectus supplement
- 15 May 24 424B3 Prospectus supplement
- 25 Apr 24 424B3 Prospectus supplement
- 11 Mar 24 424B3 Prospectus supplement
- 6 Mar 24 EFFECT Notice of effectiveness
- 5 Mar 24 424B3 Prospectus supplement
-
26 Feb 24 S-1/A IPO registration (amended)
- 15 Dec 23 S-1/A IPO registration (amended)
- 21 Nov 23 S-1 IPO registration
ENGN similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated January 29, 2024 with respect to the consolidated balance sheets as of October 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred shares and shareholders’ equity (deficit) and cash flows for the years then ended, and the related notes, of enGene Holdings Inc., included herein, and the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
February 26, 2024
Montréal, Canada